ESMO Breast Cancer 2022

ESMO Breast Cancer 2022
May 03-05, 2022
Berlin, Germany

European Society of Medical Oncology Breast Cancer 2022.

Explore more information for Gilead Oncology therapies
Results (2)

Pharmacokinetics of Sacituzumab Govitecan in Patients With Metastatic Triple-Negative Breast Cancer and Other Solid Tumors

Sacituzumab Govitecan Efficacy in Patients with Metastatic Triple-Negative Breast Cancer by HER2 Immunohistochemistry Status: Findings from the Phase 3 ASCENT Study